Original Research Paper

Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by $^{11}$C-PBR28 MR-PET

Valeria T Barletta, Elena Herranz, Costantina A Treaba, Russell Ouellette, Ambica Mehndiratta, Marco Loggia, Eric C Klawiter, Carolina Ionete, Sloane A Jacob and Caterina Mainiero

Abstract

Background: Activated microglia, which can be detected in vivo by $^{11}$C-PBR28 positron emission tomography (PET), represent a main component of MS pathology in the brain. Their role in the cerebellum is still unexplored, although cerebellar involvement in MS is frequent and accounts for disability progression.

Objectives: We aimed at characterizing cerebellar neuroinflammation in MS patients compared to healthy subjects by combining $^{11}$C-PBR28 MRI-Positron Emission Tomography (MR-PET) with 7 Tesla (T) MRI and assessing its relationship with brain neuroinflammation and clinical outcome measures.

Methods: Twenty-eight MS patients and 16 healthy controls underwent $^{11}$C-PBR28 MR-PET to measure microglia activation in normal appearing cerebellum and lesions segmented from 7 T scans. Patients were evaluated using the Expanded Disability Status Scale and Symbol Digit Modalities Test. $^{11}$C-PBR28 binding was assessed in regions of interest using 60–90 minutes standardized uptake values normalized by a pseudo-reference region in the brain normal appearing white matter. Multilinear regression was used to compare tracer uptake in MS and healthy controls and assess correlations with clinical scores.

Results: In all cerebellar regions examined, MS patients showed abnormally increased tracer uptake, which correlated with cognitive and neurological disability.

Conclusion: Neuroinflammation is widespread in the cerebellum of patients with MS and related to neurological disability and cognitive impairment.

Keywords: Cerebellum, neuroinflammation, MR-PET, microglia

Date received: 8 November 2018; revised: 5 March 2019; accepted: 8 March 2019

Introduction

Cerebellar involvement occurs early in MS, where it contributes to disease progression and predicts poor outcome. Neurological dysfunction related to cerebellar pathology in MS is generally highly disabling, since both motor and cognitive functions are affected.

Cerebellar pathology in MS is characterized by extensive cortical and white matter (WM) demyelination, and neuronal loss. In the MS brain, structural cortical and WM pathology closely associate with neuroinflammation. Apart from scattered histological examinations in progressive disease that reported microglia activation in both the cerebellar WM and cortex, the in vivo presence of neuroinflammation in the MS cerebellum is still to be characterized.

We combined $^{11}$C-PBR28 imaging on an integrated 3T MRI-Positron Emission Tomography (MR-PET) system with 7 Tesla (T) MRI to assess neuroinflammation in lesioned and normal appearing cerebellar tissue in patients at different stages of MS. $^{11}$C-PBR28 is a second-generation radiotracer with high specificity and reproducibility that binds to the 18 kDa translocator protein (TSPO), which is overexpressed in activated microglia, a main component of neuroinflammation in MS. Cerebellar lesions were

Correspondence to: C Mainiero Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA/caterina@NMR.MGH.HARVARD.EDU

Valeria T Barletta Elena Herranz Costantina A Treaba Marco Loggia Caterina Mainiero Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA Harv Medical School, Boston, MA, USA

Russell Ouellette Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA

Eric C Klawiter Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

Carolina Ionete Multiple Sclerosis Center, UMass Memorial Medical Center, Worcester, MA, USA

Sloane A Jacob Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA

Ambica Mehndiratta Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA

Marco Loggia Caterina Mainiero Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA

Caterina Mainero Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
visualized on ultra-high resolution 7T MRI, which demonstrated high sensitivity to focal lesion detection in MS.\textsuperscript{12,13} We aimed at verifying the hypothesis that activated microglia represent a main component of cerebellar pathology in MS, and at investigating whether this activation is focal or diffuse, and whether it correlates with neuroinflammation in the brain. Finally, we investigated the association between cerebellar TSPO expression and clinical measures of neurological disability and information processing speed.

Materials and methods

Standard protocol approval, patient consents, and confidentiality

The Institutional Ethics Committee and the Radioactive Drug Research Committee approved all study procedures, and subjects gave written informed consent to participate in the study. Confidentiality of study subjects has been maintained through routine precautions: we assigned codes to identify the subjects, kept our records of procedures and scans in locked security cabinets. Only information necessary to conduct the study has been distributed to the study staff; all data stored in computers have been kept in a password-protected file, available only to investigators.

Subjects

Fourteen patients with relapsing–remitting multiple sclerosis (RRMS), 14 with secondary progressive multiple sclerosis (SPMS) and 16 age-matched healthy controls (HC), all with high- or mixed-affinity binding genotype for the TSPO gene,\textsuperscript{14} were prospectively enrolled in the study. The study cohort overlaps (27/28 MS patients; 13/16 HC) with a previously published study assessing 11C-PBR28 uptake in the brain.\textsuperscript{15} General inclusion criteria were age 18–65 years, education $\geq 8$ years, absence of any treatment with benzodiazepines, no general PET and MRI contraindications, absence of major medical and/or psychiatric disorders (other than MS for patients). Inclusion criteria for MS were clinically definite MS,\textsuperscript{16} absence of clinical relapse within 3 months, no corticosteroids therapy within 1 month of study enrollment, stable disease-modifying treatment, or no treatment for at least 6 months.

Clinical evaluation

Within 1 week from imaging procedures, all patients underwent neurological disability assessment through Expanded Disability Status Scale (EDSS).\textsuperscript{17} Cognitive evaluation was performed using Symbol Digit Modalities Test (SDMT). SDMT raw scores were converted to Z-scores after correction for age and education.\textsuperscript{18}

Imaging data acquisition

Patients and HC underwent 11C-PBR28 MR-PET imaging on a Siemens (Erlangen, Germany) BrainPET system, a PET scanner operating in the bore of a 3T whole-body MRI system equipped with an eight-channel head coil.\textsuperscript{19} All subjects received an intravenous bolus injection of 11C-PBR28, which was produced in house (mean $\pm$ SD administered dose $= 11.4 \pm 0.6$ mCi in patients and $11.06 \pm 0.8$ mCi in HC, $p = 0.1$ by unpaired t-test), as previously detailed.\textsuperscript{15} The PET data were acquired in list-mode format during a 90 minutes scan. Three-dimensional (3D) multi-echo magnetization prepared rapid acquisition gradient-echo (ME-MPRAGE) images (1 mm isotropic voxels) for attenuation correction,\textsuperscript{20} co-registration of PET maps to 3T data, FreeSurfer anatomical reconstruction for brain cortex and WM segmentation, and conventional 3D fluid-attenuated inversion recovery (FLAIR) images (1 mm isotropic voxels) for brain WM lesions segmentation, were simultaneously acquired to PET images. Patients also underwent 7T MRI on a Siemens scanner using a 32-channel head coil, within ~1 week from the MR-PET session to acquire 0.6 $\times$ 0.6 $\times$ 1.5 mm voxels T1-weighted Turbo-Fast Low-Angle Shot (TFL) images for cerebellar lesion segmentation. Three MS patients did not undergo 7T imaging due to the presence of implants not approved for 7T.

MRI and PET data analysis

Cerebellar lesions were segmented from two expert raters (V.T.B. and C.A.T.) on 7T TFL images using a semiautomated method (3D Slicer v4.2.0) and defined as hypo-intensities extending at least three voxels across two consecutive slices.\textsuperscript{21} In three MS patients that did not undergo 7T imaging lesion segmentation was performed on ME-MPRAGE 3T scans. Cerebellar lesions were classified as cortical (CL), leukocortical (LCL), white matter (WML), or deep grey matter (DGML). Lesion volume was computed using FSL version 5.0.7 (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL). Masks of the whole cerebellum, cerebellar WM, and cortical grey matter (cGM) were segmented on 3T T1-weighted images on ME-MPRAGE 3T images using the automated software Volbrain (http://volbrain.upv.es).

Masks of cerebellar normal appearing white matter (NAWM) and cerebellar normal appearing cortical
grey matter (cNAGM) were obtained subtracting cerebellar lesion masks from the WM and cGM masks by FSL. To exclude that uptake in normal appearing tissue could be influenced by that in perilesional tissue, lesion masks were enlarged by 2 mm using FSL, and normalized tracer uptake values were extracted for NAWM and cNAGM before and after excluding perilesional areas. The subtracted NAWM and cNAGM masks were used in further analyses.

Brain WM lesions were segmented with 3D Slicer on FLAIR images. Brain WM and GM masks were segmented automatically by FreeSurfer on ME-MPRAGE images. Brain NAWM masks were obtained with FSL as for the cerebellum.

In-house software was used to compute voxel-wise standardized uptake values (SUV) (mean radioactivity/injected dose/weight) from the 60–90 minutes post-injection data (sampled at 1.25 mm isotropic voxel size) as previously detailed. In each subject, the SUV map was normalized by a pseudo-reference region (SUVR) located in the brain NAWM, with mean SUV in MS patients around the mean of SUV in HC. As MS is a diffuse disease lacking an anatomically consistent reference region, the pseudo-reference region was identified by a cluster-based approach. Using FSL and FreeSurfer tools, we identified clusters (minimum size 9 contiguous voxels) in the WM of HC and NAWM of patients that were within ±0.5 SD of the mean 11C-PBR28 SUV for the global WM in HC. This process was conducted separately for high- and mixed-affinity binders. No differences were found in the clusters’ SUV in patients versus HC (for high-affinity binders: mean SUV 0.71 ± 0.01 in patients vs 0.70 ± 0.01 in HC, p = 0.3; for mixed-affinity binders: mean SUV 0.54 ± 0.002 in patients vs 0.54 ± 0.002 in HC, p = 0.1 by multilinear regression covarying for age and gender).

Masks of normal appearing whole cerebellum, cerebellar NAWM and cNAGM, brain NAWM and GM, and lesions in both the brain and the cerebellum were registered to SUVR maps using FNIRT (FSL) to extract the mean SUVR. Lesions were grouped in WM lesions and cGM lesions to search for correlations with NAWM and cNAGM, respectively.

**Statistical analysis**
Statistical analysis was performed using JMP (https://www.jmp.com). Based on normality, Mann–Whitney test and Fisher’s exact test were used to compare demographics and clinical characteristics in patients versus HC, and in RRMS versus SPMS. Multilinear regression models were used (1) to compare 11C-PBR28 cerebellar uptake in patients versus HC in different regions of interest, (2) to correlate uptake in lesions and normal appearing tissue, (3) to search for associations between cerebellar uptake values and clinical metrics (disease duration, EDSS, SDMT), (4) to assess correlation between SUVR in the cerebellum and in the brain. Gender, binding affinity, age, and disease duration were included as covariates of no interest when appropriate. Matched-pairs t-test compared uptake in lesions and non-lesioned tissue in patients. A p value < 0.05 was considered statistically significant.

**Results**

**Demographic and clinical characteristics**
Demographic and clinical data of study subjects are shown in Table 1.

Patients and HC did not differ in age, gender, and binding affinity. No differences were found between the two MS sub-groups for gender and binding affinity. As expected, RRMS were younger (p = 0.005), had shorter disease duration (p < 0.001), and lower EDSS (p < 0.001) than SPMS patients. Cognitive scores were also lower in SPMS relative to RRMS cases (p < 0.001). One patient with RRMS was not able to complete the test because of important visual impairment. Twenty-two patients (12 RRMS and 10 SPMS) were on disease-modifying therapy.

**Cerebellar lesions**
Cerebellar lesions were found in the majority of MS patients: in 11/14 RRMS and 13/14 SPMS. In RRMS, most lesions were localized in the WM; in SPMS, lesions involved more frequently the cerebellar cortex, either intracortically or leukocortically. The detailed spatial localization of cerebellar lesions segmented at 7T is shown in Table 2. Figure 1(a)–(d) illustrates a few examples of cerebellar lesions at 7T. WML in the cerebellum typically involved the peduncles, and the hilar regions of the deep nuclei (Figure 1(b) and (d)); leukocortical lesions showed a broader extension in the WM and involved the cortex to smaller extent (Figure 1(a)); pure cortical lesions were seemingly confined within the folia (Figure 1(c)).

No cerebellar lesions were observed in HC.
Tracer uptake in MS compared to HCs

The $^{11}$C-PBR28 uptake was overall higher in patients relative to HC in all the cerebellar regions examined (Figure 2).

The highest $^{11}$C-PBR28 SUVRs were found in cerebellar lesions (mean SUVR $1.43 \pm 0.3$), followed by the NAWM and cNAGM in patients (mean SUVR $1.42 \pm 0.3$ and $1.38 \pm 0.3$, respectively) and WM and GM in HC (mean SUVR $1.23 \pm 0.2$ and $1.20 \pm 0.2$, respectively). Figure 3 shows $^{11}$C-PBR28 SUVR distribution across cerebellar regions in HC and MS subjects, according to their binding genotype.

When correcting for age, gender, and binding affinity, MS patients showed abnormally increased $^{11}$C-PBR28 uptake in lesions compared to the HC’s whole cerebellum ($p=0.03$), as well as in NAWM ($p=0.03$) and cNAGM ($p=0.04$) versus WM and cGM in HCs, respectively. As an outlier was present when

<table>
<thead>
<tr>
<th>Table 1. Demographic and clinical characteristics of study subjects.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
</tr>
<tr>
<td>Gender, F/M</td>
</tr>
<tr>
<td>Affinity, high/mixed</td>
</tr>
<tr>
<td>Disease duration, median</td>
</tr>
<tr>
<td>EDSS, median (range)</td>
</tr>
<tr>
<td>SDMT Z-score, median</td>
</tr>
<tr>
<td>MS treatment</td>
</tr>
<tr>
<td>Dimethyl fumarate</td>
</tr>
<tr>
<td>Natalizumab</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
</tr>
<tr>
<td>Rituximab</td>
</tr>
<tr>
<td>Interferon beta 1a</td>
</tr>
<tr>
<td>Fingolimod</td>
</tr>
<tr>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Cerebellar lesion count and volume of according to their location and disease subtype.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortical lesions</td>
</tr>
<tr>
<td>Count, median (range)</td>
</tr>
<tr>
<td>Volume, mean ± SD (range)</td>
</tr>
<tr>
<td>Number of patients</td>
</tr>
<tr>
<td>Leukocortical lesions</td>
</tr>
<tr>
<td>Count, median (range)</td>
</tr>
<tr>
<td>Volume, mean ± SD (range)</td>
</tr>
<tr>
<td>Number of patients</td>
</tr>
<tr>
<td>Deep grey matter lesions</td>
</tr>
<tr>
<td>Count, median (range)</td>
</tr>
<tr>
<td>Volume, mean ± SD (range)</td>
</tr>
<tr>
<td>Number of patients</td>
</tr>
<tr>
<td>White matter lesions</td>
</tr>
<tr>
<td>Count, median (range)</td>
</tr>
<tr>
<td>Volume, mean ± SD (range)</td>
</tr>
<tr>
<td>Number of patients</td>
</tr>
</tbody>
</table>
measuring lesion uptake in patients (Figure 3), the analysis was repeated after excluding that datum and the significant difference with HC’s whole cerebellum uptake persisted ($p = 0.03$).

To assess whether increased TSPO expression in the cerebellar NAWM and cNAGM could be driven by inflammation in perilesional tissue, the analysis was repeated excluding the perilesional area. We found...
that NAWM and cNAGM SUVR were still higher in patients than in HC \((p=0.03\) and \(p=0.04\), respectively).

Although cerebellar \(^{11}\text{C}-\text{PBR28}\) uptake was overall higher in SPMS relative to RRMS patients (NAWM: mean SUVR \(1.46 \pm 0.2\) vs \(1.37 \pm 0.3\); NAGM: mean SUVR \(1.4 \pm 0.2\) vs \(1.36 \pm 0.3\); lesions: mean SUVR \(1.51 \pm 0.3\) vs \(1.32 \pm 0.3\)), these differences were not significant \((p=0.7\) for NAWM, \(p=0.9\) for NAGM, \(p=0.4\) for lesions by linear regression models after correcting for age, gender and binding affinity). We did not find differences in \(^{11}\text{C}-\text{PBR28}\) uptake in treated versus untreated patients in any region examined.

Finally, we investigated the relationship between tracer uptake in lesions and in corresponding normal appearing tissue. Tracer uptake in cGM lesions correlated with cNAGM SUVR \((\text{coefficient} = 0.56; \text{confidence interval (CI)} = 0.35, 0.78; p < 0.0001)\), although SUVR in lesions were higher than in cNAGM \((\text{mean SUVR} 1.49 \pm 0.4\) vs \(1.38 \pm 0.3\), \(p = 0.02\) by matched-pairs \(t\)-test). A modest correlation was seen between WM lesions and NAWM uptake \((\text{coefficient} = 0.45; \text{CI} = 0.05, 0.85; p = 0.03)\), with no differences in the mean values \((\text{mean SUVR} 1.37 \pm 0.3\) vs \(1.42 \pm 0.3\), \(p = 0.4\) by \(t\)-test).

**Correlation with brain uptake values**

We found positive correlations between tracer uptake in the cerebellum and in the brain. In particular, we tested cerebellar NAWM versus brain NAWM uptake \((\text{coefficient} = 1.05; \text{CI} = 0.83, 1.27; p < 0.0001)\), cerebellar cGM versus brain cGM uptake \((\text{coefficient} = 0.95; \text{CI} = 0.77, 1.13; p < 0.0001)\), cerebellar lesions uptake versus brain WM lesions uptake \((\text{coefficient} = 0.87; \text{CI} = 0.29, 1.44; p = 0.005)\) (Figure 4).

**Correlations with clinical metrics**

No correlation was found between tracer uptake and disease duration. Both EDSS and SDMT correlated with disease duration \((p < 0.001\) and \(p = 0.01\), respectively). There was a positive correlation between EDSS and SUVR in NAWM \((p = 0.02)\), cNAGM \((p = 0.03)\), and lesions \((p = 0.02)\). We also found a negative correlation between SDMT scores and SUVR in NAWM \((p = 0.03)\), but not in cNAGM or in lesions (see Table 3 for more details).

No correlations were found between tracer uptake and cerebellar subscores for NAWM \((p = 0.2)\), cNAGM \((p = 0.1)\), and lesions \((p = 0.1)\). Figure 5 illustrates the correlations between tracer uptake and clinical metrics.
In this study, using $^{11}$C-PBR28 MR-PET and 7 T MRI, we investigated the presence of neuroinflammation in the cerebellum of RRMS and SPMS cases. We found that relative to HC, patients had abnormally increased TSPO expression, a marker of microglia activation, in both lesioned and normal appearing cerebellar WM and cortex. Neuroinflammation correlated with decreased information processing speed and neurological disability.

Previous PET studies did not report increased TSPO expression in the cerebellum of MS patients. This could be explained by the fact that previous data were obtained using $^{11}$C-PK11195, which shows significantly lower binding specificity than $^{11}$C-PBR28. Using 7 T MRI, we detected cerebellar lesions in the majority of patients. In RRMS, lesions were mainly located in the WM; in SPMS, there was a predominance of cortical and leukocortical plaques. Our findings are in line with previous reports on the presence and distribution of cerebellar lesions in the disease. We segmented lesions on T1-weighted images because previous examinations demonstrated that 7 T T1 sequences have higher sensitivity than 3 T MRI to cerebellar lesions in MS, especially those located cortically and leukocortically. Histopathology shows that demyelinated plaques can be widespread in the WM and GM of the cerebellum in MS, since the early phase of the disease. Demyelination seems to mainly involve the cerebellar cortex especially in the progressive phase; in some case, WM plaques could be undetectable even in the presence of extensive cortical demyelination.

As we previously reported, $^{11}$C-PBR28 SUVR is a reliable method for characterizing microglial pathology in MS, since it has a strong positive correlation with the radiotracer volume of distribution. We also demonstrated that MS subjects and controls showed similar levels of $^{11}$C-PBR28 plasma concentrations, and no differences in the area under the blood curves.

In our MS cohort, abnormally increased TSPO signal extensively involved the WM, both lesions and normal appearing tissue. Microglia activation can be frequently detected in WM lesions and NAWM in the brain.

### Table 3. Linear correlations between clinical metrics and tracer uptake.

<table>
<thead>
<tr>
<th></th>
<th>Disease duration</th>
<th>NAWM SUVR</th>
<th>cNAGM SUVR</th>
<th>Lesion SUVR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EDSS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coefficient</td>
<td>0.12</td>
<td>1.77</td>
<td>2.15</td>
<td>1.77</td>
</tr>
<tr>
<td>CI</td>
<td>0.06, 0.18</td>
<td>0.35, 3.20</td>
<td>0.23, 4.06</td>
<td>0.35, 3.20</td>
</tr>
<tr>
<td>$p$ value</td>
<td>&lt;0.001</td>
<td>0.02</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>SDMT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coefficient</td>
<td>–0.08</td>
<td>–2.42</td>
<td>–1.8</td>
<td>–1.45</td>
</tr>
<tr>
<td>CI</td>
<td>–015, –0.02</td>
<td>–0.64, –0.19</td>
<td>–4.12, 0.44</td>
<td>–3.60, 0.7</td>
</tr>
<tr>
<td>$p$ value</td>
<td>0.01</td>
<td>0.03</td>
<td>0.1</td>
<td>0.2</td>
</tr>
</tbody>
</table>

EDSS: expanded disability status scale; SDMT: Symbol Digit Modalities Test; NAWM: normal appearing white matter; cNAGM: normal appearing cortical grey matter; SUVR: standardized uptake values normalized by a pseudo-reference region; CI: confidence interval.
MS patients. Within lesioned tissue, inflammation is most severe in active and expanding lesions.\(^\text{27}\)

In NAWM, activated microglia mainly features the progressive disease, while it is less pronounced in the relapsing phase.\(^\text{6,7,26}\) We found similar results for cerebellar NAWM, where tracer uptake was higher in patients than in HC, especially in progressive MS. However, in our analysis, cerebellar deep nuclei were not segmented apart from the WM; thus, the SUVR in the WM was a combination of WM and deep GM uptake.

Interestingly, as observed previously for the MS brain,\(^\text{15}\) we found that microglia activation also involved the cerebellar cortex, especially lesions and SPMS disease stages, indicating that neuroinflammation is a relevant component of cerebellar

---

**Figure 5.** Scatter plots showing the correlation between tracer uptake and clinical metrics in MS patients. EDSS: expanded disability status scale; NAWM: normal appearing white matter; SUVR: standardized uptake values normalized by a pseudo-reference region; cNAGM: normal appearing cortical grey matter; SDMT: symbol digit modalities test.
cortical pathology in the disease. Ex vivo MS studies have suggested the presence of a link between cortical microglia activation, demyelination, and diffuse meningeal inflammation. Meningeal inflammation in the brain has been associated to the presence of aggregates of B-cells, organized in ectopic lymphoid follicle-like structures. These structures seem to accompany a condition of higher cortical inflammation driven by activated microglia. Although meningeal inflammation was pathologically found also in the cerebellum, evidence of follicle-like structures therein is still lacking. Future studies are needed to clarify the role of meningeal inflammation and microglia activation in cerebellar cortical pathology and its relationship with overlying brain neuroinflammation.

In our study, cerebellar neuroinflammation was widespread throughout all the regions of interest, and not strictly influenced by perilesional uptake. In addition, 11C-PBR28 uptake in the cerebellum strongly correlated with tracer uptake in the brain, suggesting that neuroinflammation in MS is diffuse to the whole CNS rather than restricted to the supra- or infratentorial compartments.

We previously found a positive correlation between EDSS and 11C-PBR28 uptake values in the brain NAWM, thalamus and cortex. This was seen also in the cerebellum, where tracer uptake diffusively correlated with EDSS. As known, cerebellar symptoms contribute to the overall EDSS score. Moreover, cerebellar structural abnormalities seem to correlate with EDSS, even in absence of clinical signs of cerebellar dysfunction, and MS patients with cerebellar signs are known to have more severe disease with poor prognosis.

We also found that lower SDMT scores correlated with increased TSPO expression in the NAWM, as previously demonstrated for the brain. Cognitive impairment with information processing speed dysfunction frequently occurs in MS, as the result of damage affecting multiple areas, including the cerebellum. Patients with motor cerebellar signs specifically showed decreased performance in attention and verbal fluency tasks, and structural abnormalities in the MS cerebellum have been shown to correlate with SDMT scores and overall cognitive function. Structural alterations in the WM can be responsible for interruption of the pathways connecting cerebellum and supratentorial structures, leading to motor and cognitive impairment. Moreover, diffusion tensor imaging analyses reported diffuse WM microstructural abnormalities in the cerebellum of MS subjects, compared to a more restricted, selective damage in the GM. There are a few limitations to our study. First, we cannot exclude that the small dimensions of some of the cerebellar lesions detected at 7T might have impacted the accuracy of tracer quantification within lesions, although the effect should be mitigated in normal appearing tissue where perilesional tissue was excluded. However, the finding that 11C-PBR28 uptake in cortical lesions was significantly higher than in cNAGM suggests that partial volume effects in lesion SUVR estimation may not be as relevant. Second, previous investigations have suggested that an endothelial binding component could affect 11C-PBR28 tracer quantification. Although this has not been definitively proven in MS, future studies will address this component for accurate tracer uptake estimation. Longitudinal investigations in larger MS cohorts are needed to better clarify the role of cerebellar glial activation in the progression of disease and in the occurrence of neurodegeneration.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C.I. has received research support from Genzyme/Sanofi, Biogen Idec, Genentech and financial compensations for scientific advisory from Genzyme/Sanofi. S.A.J. is a consultant on advisory boards for Biogen, Teva, Genentech, Celgene, Genzyme; has grant funding from Genzyme, Biogen. C. M. has received research support by Genzyme Sanofi and Serono Merck. Other authors declare no potential conflicts of interest.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by National Multiple Sclerosis Society (NMSS; RG 4729A2/1), the US Army, Department of Defense (W81XWH-13-1-0112), NIH (R01 NS078322-01-A1). E.H. was supported by NMSS fellowship (FG-1507-05459).

ORCID iD
Valeria T Barletta https://orcid.org/0000-0003-0655-9406

References
2. Eriksson M, Andersen O and Runmarker B. Long-term follow up of patients with clinically isolated


